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Objective: We characterized functional impact of narcolepsy on patients using a general
health status measure, the Sickness Impact Proﬁle (SIP). It has 136 items grouped into 12
categories and 2 dimensions.
Methods: We ascertained patients with physician-diagnosed narcolepsy in King County,
Washington using multiple overlapping methods over four years starting July 2001. We
recruited 226 patients (mean age 48 years, 65% female) who underwent in-person inter-
views and completed: Epworth Sleepiness Scale (ESS), Ullanlinna Narcolepsy Scale (UNS),
and SIP. Linear regression was used to assess correlations between measures.
Results: Mean percent of total dysfunction was higher for psychosocial dimension (13.2)
and independent categories (13.4) than physical dimension (5.0). Mean percent of total
dysfunction in descending order for categories was: Sleep and Rest (23.6), Alertness
Behavior (22.6), and Recreation and Pastimes (20.6). Ten items were endorsed by at least
a third of all patients but only two of them concerned sleep. Unexpectedly, among the top
ten items were, “My sexual activity is decreased,” and “I forget a lot, for example, things
that happened recently, where I put things, appointments.” Percent of overall dysfunction
on SIP (mean 10.3) was signiﬁcantly correlated with ESS (r¼0.36, po0.001) and UNS (r¼0.47,
po0.001). In this population-based sample, mean percent of total dysfunction on SIP in
patients with narcolepsy (10.3) was higher than previously reported in the general
population (3.6) and similar to that in other chronic disabling conditions.
Discussion: The SIP correlated with ESS and UNS, and captured unique aspects of the
impact of narcolepsy on patients.
& 2014 Brazilian Association of Sleep. Production and Hosting by Elsevier B.V. This is an
open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).ep. Production and Hosting by Elsevier B.V. This is an open access article under the CC BY-
licenses/by-nc-nd/3.0/).
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Scales that measure symptoms of narcolepsy emphasize rating
clinical features of the disease such as excessive daytime
sleepiness and cataplexy [1,2], but they may fail to capture the
full functional impact of narcolepsy or its treatments. The
Medical Outcomes Study Short Form-36 (SF-36) [3] has been used
in patients with narcolepsy to characterize more fully the effect
of the disease on physical and psychosocial spheres [4,5].
Another general health status measure, the Sickness Impact
Proﬁle (SIP) [6,7] has the potential to expand further our under-
standing of dysfunction in narcolepsy patients.
The SIP was designed to assess functional status of
patients with any chronic disease [6,7]. Its reliability and
validity have been extensively studied in neurologic [8,9] and
non-neurologic diseases [7,10], but not in patients with
narcolepsy, to our knowledge. The SIP contains 136 items
grouped in 12 categories and requires about 30 min to
complete. Each item describes a speciﬁc behavioral dysfunc-
tion, rather than a subjective self-evaluation. Patients are
instructed to endorse only those items describing dysfunc-
tion due to their disease. Each item has a weight reﬂecting
the relative severity of the dysfunction compared to other
items [11]. The 12 category scores, expressed as percents, are
the sum of the weighted scores for all the endorsed items in a
particular category divided by the maximum score, which
represents total dysfunction for that category. Some cate-
gories contribute to a physical dimension; some, to a psy-
chosocial dimension; and some independent categories, to
neither of these dimensions.
Our goals were to examine the performance of the SIP in a
population-based study of patients with physician-diagnosed
narcolepsy in King County, Washington. We wanted to
compare the information obtained from the SIP to that from
two measures used in patients with narcolepsy. We also
wanted to generate a proﬁle for patients with narcolepsy and
see how this proﬁle differed for various deﬁnitions of the
disease.2. Materials and methods
In the parent study, we attempted to identify all prevalent
cases of physician-diagnosed narcolepsy who were 18 years
and older and residing in King County, Washington as of July
1, 2001 [12]. Cases were recruited through multiple over-
lapping methods. For providers, we focused on clinicians
working in sleep disorders centers but also contacted neurol-
ogists, family medicine physicians, psychiatrists, and com-
munity clinics where patients without ﬁnancial resources
often receive care. For patients, presentations were made at
support groups and other regional meetings. Pharmacists in
King County agreed to include an information sheet about the
study with all prescriptions relevant to narcolepsy. Multi-
media advertisements and public service announcements
were also used and linked to telephone and online contact
information.
Patients identiﬁed were contacted and asked to participate
in an epidemiologic study. For those who provided writteninformed consent, trained professionals administered a struc-
tured interview. Consent to provide buccal specimens and to
obtain medical records was also requested from each partici-
pant. A total of 425 patients were entered into the narcolepsy
registry. Of these, 78 cases could not be located, 10 could not
be interviewed due to language barriers or psychiatric ill-
nesses, and 55 refused. Interviews were arranged for 282 cases,
279 of whom completed the interview and provided buccal
specimens for deoxyribonucleic acid (DNA), which was tested
for human leukocyte antigen (HLA) DQB1n0602 as detailed else-
where [13]. The University of Washington Human Subjects
Committee reviewed and approved the study.3. Data collection
Trained professionals administered in-person interviews to
patients using a standardized questionnaire that included
demographic information, the Epworth Sleepiness Scale (ESS)
[1], and the Ullanlinna Narcolepsy Scale (UNS) [2]. We deﬁned
cataplexy as present if indicated by medical record review,
self-reported cataplexy, or an afﬁrmative response to ques-
tions about experiencing muscle weakness when telling or
hearing a joke, or when laughing [14]. After the interview, the
SIP was explained to the patient, who was given the choice of
completing the SIP while the interviewer waited or to com-
plete it at a later date and return it by mail. Of the 279
patients who participated in the study, the 226 (81%) who
completed the SIP, the ESS, and the UNS are the focus of this
report.4. Analysis
Percentages were calculated for the SIP's 12 categories, two
dimensions, independent categories not included in the two
dimensions, and overall score. Results were examined for all
patients with a physician diagnosis of narcolepsy, the sub-
groups with and without cataplexy, and the subgroups with
and without HLA DQB1n0602 positivity. We conducted a two-
way analysis of variance (ANOVA) to assess the difference in
mean dysfunction scores according to cataplexy and HLA
DQB1n0602. Linear regression was also used to assess the
association between the SIP scores and cataplexy status and
HLA status while controlling for age and sex. Associations
between the SIP and the ESS and UNS were assessed with
partial correlation coefﬁcients from linear regression models
of the entire sample, which included age, sex, and HLA
DQB1n0602 status. Findings with p-values less than 0.05 were
considered signiﬁcant, and all testing was two-tailed. All
analyses were conducted in Stata (version 10.0 for Macintosh,
StataCorp, College Station, TX).5. Results
Considering the 226 patients included in these analyses, the
mean and median age was 48 years old with a range from 18
to 92 with 47% over 50 years old and 65% women. Of the 226
S l e e p S c i e n c e 7 ( 2 0 1 4 ) 5 – 1 2 7patients, 152 (67%) had cataplexy and 113 (50%) had HLA
DQB1n0602 positivity.
Among 113 who did not have the HLA marker, 58 (51.3%)
had cataplexy. Among 113 who were positive for the HLA
marker, 94 (83.2%) had cataplexy. Figs. 1 and 2 show the mean
unadjusted percent of full dysfunction for the total SIP score,
two dimensions, and 12 categories. Scores are shown for:
everyone, those with and without cataplexy restricted to
patients without HLA DQB1n0602 (Fig. 1), and those with
and without HLA DQB1n0602 positivity restricted to patients
without cataplexy (Fig. 2). In the absence of HLA DQB1n0602,
dysfunction was highest in those with cataplexy. In the
absence of cataplexy, those with HLA DQB1n0602 have lower
or similar dysfunction except for sleep and rest component of
the SIP, in which the HLA DQB1n0602 allele was associated
with a much higher level of dysfunction (Table 1).
In a two-way ANOVA, both cataplexy and HLA DQB1n0602
status were signiﬁcantly and independently associated with
total percent dysfunction (po0.001 for both factors), total
physical dysfunction (po0.02 for cataplexy; p¼0.05 for HLA
DQB1n0602 allele), total psychological dysfunction (po0.001
for both factors), and for other independent categories
of dysfunction (po0.001 for cataplexy; p¼0.01 for HLA
DQB1n0602 allele). In linear regression models with SIP scores
as the dependent variable and age, sex, cataplexy and HLA
status as the independent variables, those with cataplexy
had higher scores than those without, and those with HLAFig. 1 – Results of the Sickness Impact Proﬁle (SIP) in patients w
DQB1n0602 allele (n¼113), according to cataplexy status. Scores f
categories are the percent of total dysfunction.DQB1n0602 positivity had lower scores than those without.
Associations for cataplexy and HLA DQB1n0602 were statisti-
cally signiﬁcant for both dimension and most of the cate-
gories (Table 2). Whether a patient had one (n¼97) or two
alleles (n¼16) of HLA DQB1n0602 made little difference
(data not shown). Those with cataplexy and without HLA
DQB1n0602 positivity consistently showed the highest dys-
function (data not shown).
Patients showed greater dysfunction in the psychological
dimension and the independent categories than the physical
dimension. Much of the dysfunction fell into the independent
categories not included in either the physical or psychological
dimension. Not surprisingly, the highest scores were in the
categories for Sleep and Rest and Alertness Behavior, but
high scores were also seen in categories for Recreation and
Pastimes, Work, Emotional Behavior, and Social Interaction.
The lowest scores were in the categories for Eating, Commu-
nication, and Body Care and Movement.
The 20 items most commonly endorsed by all patients are
detailed in Table 2A, by those with cataplexy in Table 2B,
and by those with HLA DQB1n0602 positivity in Table 2C.
Considering all patients (Table 2A), 10 items were endorsed
by at least a third of the patients, but only two concerned
sleep. Tied for the third most commonly endorsed item was,
“My sexual activity is decreased,” and tied for fourth was, “I
forget a lot, for example, things that happened recently,
where I put things, appointments.” The percent of men andith physician-diagnosed narcolepsy without the HLA
or total SIP, two dimensions, independent categories, and 12
Fig. 2 – Results of the Sickness Impact Proﬁle (SIP) in patients with physician-diagnosed narcolepsy without cataplexy (n¼74),
according to presence or absence of the HLA DQB1n0602 allele. Scores for total SIP, two dimensions, independent categories,
and 12 categories are the percent of total dysfunction.
Table 1 – Regression modelsa for dimensions and components of the SIP.
Dimensions and components Cataplexy HLA DQB1n0602
p-Value p-Value R2
Overall dysfunction o0.001 0.001 0.10
Total physical dysfunction 0.005 0.004 0.15
Body Care and Movement 0.033 0.018 0.11
Mobility o0.001 o0.001 0.11
Ambulation 0.078 0.109 0.17
Total psychosocial dysfunction o0.001 0.001 0.11
Emotional Behavior 0.008 0.026 0.07
Social Interaction 0.001 0.007 0.06
Alertness Behavior o0.001 o0.001 0.14
Communication 0.053 0.012 0.04
Total other dysfunction o0.001 0.013 0.08
Sleep and Rest 0.001 0.617 0.05
Home Management o0.001 0.007 0.10
Work 0.015 0.013 0.05
Recreation and Pastimes 0.002 0.060 0.06
Eating 0.086 0.160 0.03
a Adjusted for cataplexy, HLA DQB1n0602, age and sex.
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signiﬁcantly different. Eighteen of the top 20 items were the
same for all patients (Table 2A) and the two subgroups ofthose with cataplexy (Table 2B) and those with HLA
DQB1n0602 positivity (Table 2C), although the order of items
differed.
Table 2 – The 20 most commonly endorsed items on the Sickness Impact Proﬁle (SIP) by (A) all patients, (B) those with
cataplexy, and (C) those with HLA DQB1n0602 positivity.
(A) Among all patients (n¼226)
Itema Weight Dysfunctional behavior Percent
sr7 60 I sleep or nap more during the day 46
rp2 36 I am going out for entertainment less often 43
hm2 44 I am doing less of the regular daily work around the house than I would usually do 39
si9 51 My sexual activity is decreased 39
rp1 39 I do my hobbies and recreation for shorter periods of time 39
si6 36 I am doing fewer social activities with groups of people 37
ab4 67 I do not ﬁnish things I start 37
ab7 78 I forget a lot, for example, things that happened recently, where I put things, appointments 37
sr6 61 I sleep less at night, for example, wake up too early, don’t fall asleep for a long time, awaken frequently 35
hm1 54 I do work around the house only for short periods of time or rest often 35
sr5 84 I sit around half-asleep 33
sr2 49 I sit during much of the day 29
si1 44 I am going out less to visit people 28
a1 48 I walk shorter distances or stop to rest often 28
ab10 80 I have difﬁculty doing activities involving concentration and thinking 28
rp7 43 I am cutting down on some of my usual physical recreation or activities 28
sr4 58 I lie down more often during the day in order to rest 27
rp6 33 I am doing fewer community activities 26
ab8 67 I do not keep my attention on any activity for long 23
bcm12 30 I change position frequently 22
(B) Among patients with cataplexy (n¼152)
Itema Weight Dysfunctional behavior Percent
si6 36 I am doing fewer social activities with groups of people 44
rp2 36 I am going out for entertainment less often 44
sr6 61 I sleep less at night, for example, wake up too early, don't fall asleep for a long time, awaken
frequently
43
sr7 60 I sleep or nap more during the day 43
ab7 78 I forget a lot, for example, things that happened recently, where I put things, appointments 43
hm2 44 I am doing less of the regular daily work around the house than I would usually do 42
si9 51 My sexual activity is decreased 41
rp1 39 I do my hobbies and recreation for shorter periods of time 41
hm1 54 I do work around the house only for short periods of time or rest often 39
ab4 67 I do not ﬁnish things I start 39
sr2 49 I sit during much of the day 36
sr5 84 I sit around half-asleep 36
rp7 43 I am cutting down on some of my usual physical recreation or activities 35
si1 44 I am going out less to visit people 34
ab10 80 I have difﬁculty doing activities involving concentration and thinking 34
a1 48 I walk shorter distances or stop to rest often 31
rp6 33 I am doing fewer community activities 31
ab8 67 I do not keep my attention on any activity for long 30
bcm12 30 I change position frequently 28
ab2 75 I have more minor accidents, for example, drop things, trip and fall, bump into things 27
(C) Among patients with HLA DQB1n0602 positivity (n¼113)
Itema Weight Dysfunctional behavior Percent
sr7 60 I sleep or nap more during the day 44
rp2 36 I am going out for entertainment less often 40
si9 51 My sexual activity is decreased 39
hm2 44 I am doing less of the regular daily work around the house than I would usually do 38
rp1 39 I do my hobbies and recreation for shorter periods of time 37
si6 36 I am doing fewer social activities with groups of people 36
sr6 61 I sleep less at night, for example, wake up too early, don’t fall asleep for a long time, awaken frequently 35
hm1 54 I do work around the house only for short periods of time or rest often 35
ab4 67 I do not ﬁnish things I start 34
ab7 78 I forget a lot, for example, things that happened recently, where I put things, appointments 32
sr2 49 I sit during much of the day 31
sr5 84 I sit around half-asleep 29
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Table 2 (continued )
(C) Among patients with HLA DQB1n0602 positivity (n¼113)
Itema Weight Dysfunctional behavior Percent
sr4 58 I lie down more often during the day in order to rest 27
si1 44 I am going out less to visit people 27
a1 48 I walk shorter distances or stop to rest often 27
ab10 80 I have difﬁculty doing activities involving concentration and thinking 26
rp7 43 I am cutting down on some of my usual physical recreation or activities 26
rp6 33 I am doing fewer community activities 25
bcm12 30 I change position frequently 22
rp3 59 I am cutting down on some of my usual inactive recreation and pastimes, for example, watching TV,
playing cards, reading
21
a The SIP items describe dysfunctional behavior endorsed by patient with narcolepsy. Each item has a weight reﬂecting the relative severity of
the dysfunction compared to other items. The percent of patients endorsing an item out of all the patients is given in the ﬁnal column. The
letters stand for categories (see Figs. 1 and 2 and Table 3), and the number represents an item in the category.
Table 3 – Partial correlations between ESS and UNS scales and a general health status measure, the Sickness Impact
Proﬁle (SIP).
Scales
Epworth Sleepiness Ullanlinna Narcolepsy
Percent of total dysfunction Correlationa p-Value Correlationa p-Value
Total SIP 0.36 o0.001 0.47 o0.001
Physical dimension 0.26 o0.001 0.35 o0.001
Body Care and Movement (bcm) 0.24 o0.001 0.29 o0.001
Mobility (m) 0.27 o0.001 0.36 o0.001
Ambulation (a) 0.15 0.023 0.26 o0.001
Psychosocial dimension 0.30 o0.001 0.39 o0.001
Emotional Behavior (eb) 0.23 o0.001 0.28 o0.001
Social Interactions (si) 0.30 o0.001 0.37 o0.001
Alertness Behavior (ab) 0.24 o0.001 0.36 o0.001
Communication (c) 0.17 0.009 0.27 o0.001
Independent categories 0.40 o0.001 0.52 o0.001
Sleep and Rest (sr) 0.39 o0.001 0.51 o0.001
Home Management (hm) 0.31 o0.001 0.42 o0.001
Work (w) 0.25 o0.001 0.29 o0.001
Recreation and Pastimes (rp) 0.28 o0.001 0.42 o0.001
Eating (e) 0.24 o0.001 0.24 o0.001
a Partial correlation coefﬁcients from linear regression models including age, sex, and HLA DQB1n0602 status.
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UNS and the SIP scores are presented in Table 3 controlling
for age, sex, and HLA DQB1n0602 status. All correlations were
signiﬁcant. Correlations were stronger for the UNS than for
the ESS for the total score, two dimensions and 11 of the 12
categories. As expected, the category with the strongest
correlation with the ESS and UNS measures was Sleep and
Rest, and the three categories with the weakest correlations
were Ambulation, Communication, and Eating.6. Discussion
Results from this general health status measure suggest that
narcolepsy substantially impairs function, psychosocial morethan physical. The impact of this disease on patients' daily
lives may be underappreciated because the relatively pre-
served physical function gives others the impression that
patients with narcolepsy are healthy or do not have a serious
disease. Among patients with cataplexy, the impairment of
function was greater. On the other hand, among patients
with HLA DQB1n0602 positivity, the impairment of function
was less. Whether cataplexy and HLA status identify sub-
types of narcolepsy with possibly different etiologies remains
to be determined. Recent publications have raised questions
about the importance of cataplexy. In one, partial loss of
hypocretin (orexin) cells was documented on neuropatholo-
gic examination in narcolepsy without cataplexy [15]. In
another, a subset of patients with hypersomnia who did not
meet criteria for narcolepsy had the same genetic proﬁle
S l e e p S c i e n c e 7 ( 2 0 1 4 ) 5 – 1 2 11described in patients with narcolepsy with cataplexy, namely
positivity for HLA DQB1n0602 and T-cell receptor alpha
(TCRA) locus [16].
The ESS and the UNS focus on clinical features. The ESS
assesses sleepiness, while the UNS includes questions about
cataplexy, perhaps explaining why correlations with the SIP
were stronger for UNS than the ESS. Although these scales
were correlated with the SIP, the correlation was not perfect
suggesting that the SIP may be capturing other information
about the impact of the disease on a person's function and
providing a richer description of narcolepsy's proﬁle. The SIP
also allows comparison across diseases, although caution is
needed because of the differences in populations studied. The
mean overall SIP score in these patients was 10.3. The compar-
able ﬁgure was 3.6 in a general population; 15.6 in a clinic-
based series of patients with rheumatoid arthritis [10]; and 16.8
in a clinic-based series of patients with Parkinson's disease [8].
The Psychosocial Dimension score was 13.2 with narcolepsy,
11.3 with rheumatoid arthritis, 19.4 with Parkinson's disease.
Many of the items endorsed in the SIP could be anticipated
based on the key clinical feature of excessive daytime sleepi-
ness. Less easily explained is that over a third of patients
endorsed sexual and memory dysfunction. Sexual dysfunction
has been noted previously [17] but not emphasized in descrip-
tions of the disease. Although memory has been found to be
preserved on neuropsychological testing, despite complaints of
memory problems, executive function may be impaired in
patients with narcolepsy [18]. Whether these dysfunctions
relate to sleep deprivation, some direct effect of narcolepsy,
or some medication side effect cannot be determined by this
study, but the issue of cause deserves further consideration.
Interventions aimed at improving these dysfunctions may
improve the quality of life for patients with narcolepsy.
Although the study was population-based, we did not recruit
all patients with physician-diagnosed narcolepsy into the full
study so the responses of those who participated may have
differed from those who did not participate. We did not perform
standardized sleep studies in all patients, but the region's sleep
medicine experts made most of the diagnoses [12], and our
results were similar when restricted to patients with cataplexy.
We also did not have biological specimens beyond DNA in these
patients, such as hypocretin-1 levels in the cerebrospinal ﬂuid.
This study was cross-sectional, and longitudinal studies would
be needed to judge the responsiveness of the SIP to changes
judged important by the patients and providers.
The SIP is well validated but has been largely replaced by
briefer screens such as the SF-36, which has been used
in patients with narcolepsy. We would encourage others
to explore using the SIP in populations of patients with
narcolepsy because of the richness of descriptive information
it provides and its simplicity. Inclusion of the SIP or some
other general health status measures should be considered in
clinical trials to detect unanticipated positive or negative
effects of a treatment on daily function.Financial support
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